Compare Novartis AG (NVS) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Sirius XM Holdings Inc — how do they compare? Novartis AG trades at $139.89 (market cap $262.64B), while Sirius XM Holdings Inc trades at $28.71 (market cap $9.71B). The key difference: Novartis AG is far larger — about 27× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| NVS | SIRI | |
|---|---|---|
Market Cap | $262.64B | $9.71B |
Sector | Health | Media |
52-Week High | $168.62 | $32.59 |
52-Week Low | $121.80 | $19.92 |
Enterprise Value | $303.97B | $18.99B |
Dividend Yield | 3.44% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Sirius XM Holdings Inc. (SIRI) trades at $28.80, down 0.66% today, with a bullish technical signal from moving averages and a consensus analyst price target of $34.86. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Financials show a net income margin of 10.23% for 2025, with revenue at $8.56B, while the balance sheet indicates a debt-to-asset ratio improvement to 35.63% in 2025. Recent news highlights a YouTube partnership expected to boost EBITDA by 2029.
The outlook for SIRI is positive, supported by analyst upgrades and institutional buying, but risks include competitive pressures in audio streaming and reliance on advertising growth. The stock's valuation metrics, such as a P/E of 11.57 and P/B of 0.82, suggest potential upside if earnings improve, though volatility from market sentiment remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
